Celcuity Inc
NASDAQ:CELC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Celcuity Inc
NASDAQ:CELC
|
US |
|
L
|
LTC Properties Inc
SWB:LTP
|
US |
|
Sun Hung Kai Properties Ltd
HKEX:16
|
HK |
|
A
|
American States Water Co
SWB:FDK
|
US |
|
Z
|
Zillow Group Inc
F:0ZG2
|
US |
|
Thungela Resources Ltd
OTC:TNGRF
|
ZA |
|
T
|
TUI AG
F:TUI1
|
DE |
Celcuity Inc
Celcuity Inc. is a clinical-stage biotechnology company that develops cancer drugs aimed at specific tumor signaling pathways. Its main work is to identify which patients are most likely to respond to a treatment and then advance drugs that block the biological signals helping cancer cells grow. The company’s lead programs are built around targeted therapies rather than broad chemotherapy, so its business depends on matching the right drug to the right cancer biology. Celcuity does not sell a wide range of commercial medicines. It makes money mainly through drug development activities, which can include licensing, collaboration payments, and future product sales if its candidates win approval. Its research platform is used to study patient tumor samples and help guide clinical trial design, which gives the company a role both as a drug developer and as a precision-medicine toolmaker. For investors, the key point is that Celcuity sits in the high-risk, high-reward part of biotech. It is trying to turn lab and clinical data into approved cancer treatments that address patients with specific molecular markers. That makes its business model different from a traditional drugmaker: most of its value depends on successful clinical testing, regulatory approval, and eventual adoption by oncologists and hospitals.
Celcuity Inc. is a clinical-stage biotechnology company that develops cancer drugs aimed at specific tumor signaling pathways. Its main work is to identify which patients are most likely to respond to a treatment and then advance drugs that block the biological signals helping cancer cells grow. The company’s lead programs are built around targeted therapies rather than broad chemotherapy, so its business depends on matching the right drug to the right cancer biology.
Celcuity does not sell a wide range of commercial medicines. It makes money mainly through drug development activities, which can include licensing, collaboration payments, and future product sales if its candidates win approval. Its research platform is used to study patient tumor samples and help guide clinical trial design, which gives the company a role both as a drug developer and as a precision-medicine toolmaker.
For investors, the key point is that Celcuity sits in the high-risk, high-reward part of biotech. It is trying to turn lab and clinical data into approved cancer treatments that address patients with specific molecular markers. That makes its business model different from a traditional drugmaker: most of its value depends on successful clinical testing, regulatory approval, and eventual adoption by oncologists and hospitals.
Clinical progress: Celcuity said gedatolisib continues to make major progress, highlighting positive Phase III VIKTORIA-1 mutant-cohort data and calling the program well positioned for a potential approval and launch in the third quarter.
Trial expansion: The company expanded VIKTORIA-2 to include a second study in endocrine-sensitive first-line breast cancer, broadening its plan to study nearly all first-line patients regardless of endocrine sensitivity or PIK3CA status.
Launch prep: Management said commercial readiness is well underway, with all oncology sales specialists now hired and onboarded and payer discussions already in progress.
Financial loss: First-quarter net loss widened to $52.8 million, or $0.97 per share, from $37.0 million a year ago, mainly as spending increased ahead of launch.
Cash position: Celcuity ended the quarter with $387.1 million in cash, cash equivalents and short-term investments and said that, together with debt draws, it expects to fund operations through 2027.
FDA timing: Management said nothing in its FDA interactions suggests it will miss the July 17 PDUFA date, while keeping details of labeling and agency discussions limited.
